Adcendo

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer

by

Dr. Ottesen brings in-depth global clinical development expertise in oncology, including biologics, small molecules, immunotherapies and ADCs Adcendo further builds its world class team to accelerate development of lead ADC asset uPARAP and to expand its first-in-class ADC pipeline COPENHAGEN, Denmark, June 20, 2023 /PRNewswire/ — Adcendo ApS (“Adcendo”), a biotech company focused on the development … Read more

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline

by

Strengthening of strategic option license agreement to cover additional novel ADC targets COPENHAGEN, Denmark, May 30, 2023 /PRNewswire/ — Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, announced the expansion of its current collaboration with Duality Biologics (“Duality”), … Read more